Cantor Fitzgerald Downgrades Aclaris Therapeutis (ACRS) to Neutral
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 11/4/2026
- Wall Street rallies after Democrats win Congress; data center stocks slide
- What the Democratic sweep in the midterms means for markets
- SpaceX, Tesla slide as election risks mount, Morgan Stanley turns bullish
- CVS Health plans to split into two public companies by 2028
- AI sector outlook darkens as Democrat wins threaten $900B capex cycle
Tweet
Share
E-mailGet Alerts ACRS Hot Sheet
Price: $3.70 -1.07%
Rating Summary:
15 Buy, 3 Hold, 0 Sell
Rating Trend:
Up
Today's Overall Ratings:
Up: 16 | Down: 25 | New: 12
Rating Summary:
15 Buy, 3 Hold, 0 Sell
Rating Trend:
Up
Today's Overall Ratings:
Up: 16 | Down: 25 | New: 12
Join SI Premium – FREE
Cantor Fitzgerald analyst Louise Chen downgraded Aclaris Therapeutis (NASDAQ: ACRS) from Overweight to Neutral.
For an analyst ratings summary and ratings history on Aclaris Therapeutis click here. For more ratings news on Aclaris Therapeutis click here.
Shares of Aclaris Therapeutis closed at $0.64 yesterday.
You May Also Be Interested In
- KeyBanc Downgrades Vistra Energy (VST) to Sector Weight
- Lake Street Downgrades Flux Power Holdings (FLUX) to Hold
- Keefe, Bruyette & Woods Downgrades Cipher Mining (CIFR) to Market Perform
Create E-mail Alert Related Categories
DowngradesSign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!
